xAI Restricts Grok Image Editing After Sexualized AI Images Trigger Global Scrutiny 
Toyota Industries Buyout Faces Resistance as Elliott Rejects Higher Offer 
China Considers New Rules to Limit Purchases of Foreign AI Chips Amid Growing Demand 
Jamie Dimon Signals Possible Five More Years as JPMorgan CEO Amid Ongoing Succession Speculation 
TSMC Shares Hit Record High as AI Chip Demand Fuels Strong Q4 Earnings 
Microsoft Strikes Landmark Soil Carbon Credit Deal With Indigo Carbon to Boost Carbon-Negative Goal 
Elon Musk Seeks $134 Billion in Lawsuit Against OpenAI and Microsoft Over Alleged Wrongful Gains 
Publishers Seek to Join Lawsuit Against Google Over Alleged AI Copyright Infringement 
Syrah Resources and Tesla Extend Deadline on Graphite Supply Dispute to March 
White House Pressures PJM to Act as Data Center Energy Demand Threatens Grid Reliability 
U.S. Lawmakers Raise Alarm Over Trump Approval of Nvidia AI Chip Sales to China 
TikTok Expands AI Age-Detection Technology Across Europe Amid Rising Regulatory Pressure 
Taiwan Issues Arrest Warrant for OnePlus CEO Over Alleged Illegal Recruitment Activities 
Sanofi Gains China Approval for Myqorzo and Redemplo, Strengthening Rare Disease Portfolio 
U.S. Moves to Expand Chevron License and Control Venezuelan Oil Sales 
One Percent Rule Checklist For Safer Forex Trading Risk 
Anthropic Appoints Former Microsoft Executive Irina Ghose to Lead India Expansion 
SYDNEY, Australia, April 18, 2017 -- Prima BioMed Ltd (ASX:PRR) (NASDAQ:PBMD) (“Prima” or the “Company”) today announced that approval has been granted for the third cohort of its Phase I clinical trial for IMP321 in combination with KEYTRUDA® being conducted in Australia. The third cohort will recruit six patients with unresectable or metastatic melanoma.
Interim data results from the first patient cohort released in December 2016 indicate IMP321 at the 1mg dose level is safe and well tolerated. Out of the six patients in the first cohort (all with suboptimal response to KEYTRUDA® monotherapy) two patients had a partial or complete radiological tumour response according to immune related response criteria (irRC).
The positive safety profile was also confirmed in the second cohort dosed with 6 mg of IMP321. None of the 6 patients treated with KEYTRUDA® plus IMP321 at this higher dose level experienced any serious adverse reaction nor dose limiting toxicity. As a result, the independent Drug Safety Monitoring Board (DSMB) has granted approval for the third cohort, at the 30mg dose level, to commence with the first patient to be dosed in due course.
TACTI-mel (Two ACTive Immunotherapeutics in melanoma) is a multicentre, open label, Phase I study in which patients with unresectable or metastatic melanoma will be dosed with IMP321 in combination with the PD-1 checkpoint inhibitor pembrolizumab (KEYTRUDA®). The study will evaluate safety as the primary endpoint and anti-tumour activity and the immune response to the combination as secondary endpoints.
About IMP321
IMP321, a first-in-class Antigen Presenting Cell (APC) activator based on the immune checkpoint LAG-3, represents one of the first proposed active immunotherapy drugs in which the patient’s own immune system is harnessed to respond to tumour antigenic debris created by chemotherapy. As an APC activator IMP321 boosts the network of dendritic cells in the body that can respond to tumour antigens for a better anti-tumour CD8 T cell response.
About Prima BioMed
Prima BioMed is listed on the Australian Securities Exchange and on the NASDAQ in the US. For further information please visit www.primabiomed.com.au.
For further information please contact: U.S. Investors: Matthew Beck, The Trout Group LLC +1 (646) 378-2933; [email protected] Australian Investors/Media: Mr Matthew Gregorowski, Citadel-MAGNUS +61 2 8234 0105; [email protected]
